Talphera

Talphera Revenue

The The revenue of Talphera (TLPH) as of Nov 7, 2026 is 28,000.00 USD.

Revenue

28,000.00USD

Last updated:

In 2025, Talphera's sales reached 28,000.00 USD, a % difference from the 0.00 USD sales recorded in the previous year.

Revenue at Talphera has contracted by 22.9% per year over the past 14 years to 28,000.00 USD.

The Talphera Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2024
0.00 USD
Jan 1, 2025
28,000.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
447,000.00 USD
Jan 1, 2028 (e)
13.73 M USD
Jan 1, 2029 (e)
37.10 M USD
Jan 1, 2030 (e)
65.23 M USD
Jan 1, 2031 (e)
118.93 M USD
The Talphera Revenue history
YEARRevenueYoY
est118.93 MUSD+82.34%
est65.23 MUSD+75.81%
est37.10 MUSD+170.22%
est13.73 MUSD+2,971.48%
est447,000.00USD—
est0.00USD-100.00%
28,000.00USD—
0.00USD-100.00%
651,000.00USD-63.24%
1.77 MUSD+368.52%
378,000.00USD-93.02%
5.42 MUSD+136.61%
2.29 MUSD+6.42%
2.15 MUSD-73.10%
8.00 MUSD-53.94%
17.36 MUSD-9.89%
19.26 MUSD+269.24%
5.22 MUSD-82.32%
29.50 MUSD+1,132.33%
2.39 MUSD+123.32%
1.07 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Revenue

Talphera Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
0.00 USD
-15.25 M USD
-13.00 M USD
Jan 1, 2025
28,000.00 USD
-13.48 M USD
-14.29 M USD
Jan 1, 2026 (e)
0.00 USD
-8.27 M USD
-9.56 M USD
Jan 1, 2027 (e)
447,000.00 USD
-8.69 M USD
-10.41 M USD
Jan 1, 2028 (e)
13.73 M USD
-5.00 M USD
-5.90 M USD
Jan 1, 2029 (e)
37.10 M USD
2.88 M USD
2.80 M USD
Jan 1, 2030 (e)
65.23 M USD
11.12 M USD
11.34 M USD
Jan 1, 2031 (e)
118.93 M USD
0.00 USD
46.59 M USD

Talphera Margins

Talphera stock margins

The Talphera margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Talphera. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Talphera.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
-48,157.14 %
-51,035.71 %
Jan 1, 2026 (e)
100.00 %
- %
- %
Jan 1, 2027 (e)
100.00 %
-1,945.01 %
-2,328.41 %
Jan 1, 2028 (e)
100.00 %
-36.45 %
-43.00 %
Jan 1, 2029 (e)
100.00 %
7.75 %
7.54 %
Jan 1, 2030 (e)
100.00 %
17.05 %
17.39 %
Jan 1, 2031 (e)
100.00 %
0.00 %
39.18 %

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Talphera's Sales Figures

The sales figures of Talphera originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Talphera’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Talphera's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Talphera’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Talphera stock

The revenue of Talphera is 28,000.00 USD in 2025.

On Eulerpool you can find the complete historical development of The revenue Talphera since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Talphera historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Talphera

All Key Metrics — Talphera